Ma HS - Search Results

1

All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.

Ma HS, Greenblatt SM, Shirley CM, Duffield AS, Bruner JK, Li L, Nguyen B, Jung E, Aplan PD, Ghiaur G, Jones RJ, Small D. Ma HS, et al. Blood. 2016 Jun 9;127(23):2867-78. doi: 10.1182/blood-2015-05-646786. Epub 2016 Apr 21. Blood. 2016. PMID: 27103744 Free PMC article.

2

FLT3/D835Y mutation knock-in mice display less aggressive disease compared with FLT3/internal tandem duplication (ITD) mice.

Bailey E, Li L, Duffield AS, Ma HS, Huso DL, Small D. Bailey E, et al. Among authors: ma hs. Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21113-8. doi: 10.1073/pnas.1310559110. Epub 2013 Nov 19. Proc Natl Acad Sci U S A. 2013. PMID: 24255108 Free PMC article.

3

FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia.

Ma HS, Nguyen B, Duffield AS, Li L, Galanis A, Williams AB, Brown PA, Levis MJ, Leahy DJ, Small D. Ma HS, et al. Cancer Res. 2014 Sep 15;74(18):5206-17. doi: 10.1158/0008-5472.CAN-14-1028. Epub 2014 Jul 24. Cancer Res. 2014. PMID: 25060518 Free PMC article.

4

Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies.

Bruner JK, Ma HS, Li L, Qin ACR, Rudek MA, Jones RJ, Levis MJ, Pratz KW, Pratilas CA, Small D. Bruner JK, et al. Among authors: ma hs. Cancer Res. 2017 Oct 15;77(20):5554-5563. doi: 10.1158/0008-5472.CAN-16-2593. Epub 2017 Sep 18. Cancer Res. 2017. PMID: 28923853 Free PMC article.

5

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.

Galanis A, Ma H, Rajkhowa T, Ramachandran A, Small D, Cortes J, Levis M. Galanis A, et al. Blood. 2014 Jan 2;123(1):94-100. doi: 10.1182/blood-2013-10-529313. Epub 2013 Nov 13. Blood. 2014. PMID: 24227820 Free PMC article. Clinical Trial.

6

TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo.

Ma H, Nguyen B, Li L, Greenblatt S, Williams A, Zhao M, Levis M, Rudek M, Duffield A, Small D. Ma H, et al. Blood. 2014 Mar 6;123(10):1525-34. doi: 10.1182/blood-2013-08-523035. Epub 2014 Jan 9. Blood. 2014. PMID: 24408321 Free PMC article.

7

FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.

Nguyen B, Williams AB, Young DJ, Ma H, Li L, Levis M, Brown P, Small D. Nguyen B, et al. Oncotarget. 2017 Feb 14;8(7):10931-10944. doi: 10.18632/oncotarget.14539. Oncotarget. 2017. PMID: 28077790 Free PMC article.

8

Combination of ATO with FLT3 TKIs eliminates FLT3/ITD+ leukemia cells through reduced expression of FLT3.

Nagai K, Hou L, Li L, Nguyen B, Seale T, Shirley C, Ma H, Levis M, Ghiaur G, Duffield A, Small D. Nagai K, et al. Oncotarget. 2018 Aug 31;9(68):32885-32899. doi: 10.18632/oncotarget.25972. eCollection 2018 Aug 31. Oncotarget. 2018. PMID: 30250637 Free PMC article.

9

Potential role for all-trans retinoic acid in nonpromyelocytic acute myeloid leukemia.

Ma HS, Robinson TM, Small D. Ma HS, et al. Int J Hematol Oncol. 2016 Dec;5(4):133-142. doi: 10.2217/ijh-2016-0015. Epub 2017 Mar 14. Int J Hematol Oncol. 2016. PMID: 30302214 Free PMC article. Review.

10

Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia.

Lim Y, Gondek L, Li L, Wang Q, Ma H, Chang E, Huso DL, Foerster S, Marchionni L, McGovern K, Watkins DN, Peacock CD, Levis M, Smith BD, Merchant AA, Small D, Matsui W. Lim Y, et al. Sci Transl Med. 2015 Jun 10;7(291):291ra96. doi: 10.1126/scitranslmed.aaa5731. Sci Transl Med. 2015. PMID: 26062848 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

93 results

Search Page

Filters